A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-S in Patients With Ischemic Stroke in the Recovery Phase
Latest Information Update: 03 Oct 2025
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy Shanghai IxCell Biotechnology (Primary)
- Indications Ischaemic stroke
- Focus Therapeutic Use
- Sponsors Shanghai IxCell Biotechnology
Most Recent Events
- 03 Oct 2025 New trial record